BPC-157: The “Body Protection Compound”

LEGAL & MEDICAL DISCLAIMER: The information provided on this page by PeptideMatch.io is intended solely for educational and informational purposes. It does not constitute, and should not be interpreted as, professional medical advice, diagnosis, or treatment. Always consult a licensed physician or qualified healthcare provider before beginning any peptide therapy or making changes to an existing treatment plan. PeptideMatch.io does not prescribe, dispense, or endorse any specific therapeutic protocol. Individual results may vary, and no outcomes are guaranteed.

What Is BPC-157?

If you follow regenerative medicine, sports recovery, or gut health research, you have almost certainly come across BPC-157. It shows up in conversations about healing injuries that won’t respond to conventional treatment, protecting the gut from damage, and even supporting brain health. The range of claims can feel almost too broad to be believable.

But here is the thing: the science behind BPC-157 is more substantial than most people realize, and more limited than its biggest advocates suggest. That nuance is worth understanding.

BPC-157, short for Body Protection Compound-157, is a lab-made peptide, a short chain of 15 amino acids (the building blocks of proteins). It was first identified by researcher Predrag Sikiric and colleagues in 1993, derived from a protein that occurs naturally in human stomach fluid.¹ Most peptides break down quickly inside the body, but BPC-157 is unusually stable, even in the acidic environment of the stomach. That stability is part of what makes it such a popular subject of study, with research spanning gut health, tendon and muscle repair, brain function, and inflammation.¹

Fast Facts

FULL NAME: BPC-157 (Body Protection Compound-157; also known as PL 10, PLD 116, and Bepecin) CLASS: Synthetic pentadecapeptide; cytoprotective PRIMARY ACTION: Synthetic peptide derived from a protein found in stomach fluid; research suggests it may promote tissue repair and reduce inflammation ADMINISTRATION: Investigational; swallowed in research settings HALF-LIFE: Approximately 4 hours (variable across formulations) RESEARCH: Wound healing, tendon repair, gastrointestinal disorders, and neuroprotection REGULATORY STATUS: Investigational; not FDA approved for any indication

How Does BPC-157 Work?

Rather than acting through a single pathway, BPC-157 functions as what researchers call a pleiotropic agent, meaning it influences multiple physiological systems at once. That is part of why it has attracted interest across so many different medical disciplines.^1,2

1. Angiogenesis and Blood Vessel Formation

One of BPC-157’s best-documented effects is encouraging the body to grow new blood vessels, a process called angiogenesis. It does this by activating receptors on cells that drive new vessel formation, and by boosting nitric oxide, a molecule that helps blood vessels relax and improves blood flow.² Better blood supply matters most in tissues that normally heal slowly, like tendons and ligaments, because they have very limited circulation to begin with. This is one of the main reasons BPC-157 has drawn so much interest in orthopedics and sports medicine.³

2. Growth Hormone Receptor Upregulation

BPC-157 also appears to make tendon cells more responsive to growth hormone, the body’s main signal for tissue building and repair. By increasing the number of receptors that “listen” for growth hormone, BPC-157 may help amplify the body’s own repair signals, which could explain some of the tendon-healing effects seen in studies.⁴

3. ERK1/2 Signaling and Fibroblast Activity

BPC-157 activates a cellular signaling pathway (called ERK1/2) that tells cells to multiply, mature, and stay alive. By switching this pathway on, BPC-157 prompts fibroblasts (the cells that make collagen and other structural proteins) to ramp up production of the materials needed to rebuild connective tissue.²

4. Anti-Inflammatory and Antioxidant Properties

Beyond its regenerative functions, BPC-157 has been shown to reduce systemic inflammation by modulating pro-inflammatory cytokines such as IL-6 and TNF-alpha. It also exhibits antioxidant activity, stabilizing free radical scavengers and counteracting oxidative stress, a key driver of chronic disease and impaired healing.¹

5. Neurotransmitter Modulation

Within the central nervous system, BPC-157 has been shown to interact with dopaminergic and serotonergic pathways. It has demonstrated the ability to modulate dopamine levels, counteract the behavioral effects of amphetamine, and exhibit antidepressant-like properties in preclinical models, suggesting a potential role in neuropsychiatric health.¹

What Does the Research Say?

The range of BPC-157 research is impressive for a compound that has not yet been through large-scale human clinical trials. The table below summarizes the main areas being studied and where the evidence currently stands.

A 2025 systematic review published in HSS Journal, the journal of Hospital for Special Surgery, concluded that BPC-157 “modulates cell growth, proliferation, survival, anti-inflammatory, and angiogenesis pathways,” and that it “has improved outcomes in muscle, tendon, ligament, and bone healing” across preclinical models.⁵ The same review underscored the critical need for well-designed human trials to validate these findings.

THERAPEUTIC AREA	WHAT RESEARCH SUGGESTS	EVIDENCE LEVEL
Musculoskeletal Healing	Accelerated tendon, ligament, and skeletal muscle repair; improved tendon-to-bone integration; enhanced collagen synthesis	PRECLINICAL
Gastrointestinal Protection	Healing of gastric ulcers, protection of gut endothelium, mitigation of NSAID and alcohol-induced damage, IBD models	PHASE II TRIALS
Wound Healing	Accelerated closure of burns, excisional wounds, and fistulas; enhanced neovascularization and epithelialization	PRECLINICAL
Neurological Support	Neuroprotective effects; modulation of dopamine and serotonin; antidepressant-like activity in animal models	PRECLINICAL
Anti-Inflammatory	Reduction of IL-6 and TNF-alpha; antioxidant activity; protection against NSAID-induced systemic damage	PRECLINICAL
Cardiovascular & Vascular	Improved blood vessel formation; protection of endothelial cells; potential benefits in ischemic conditions	PRECLINICAL
Joint & Orthopedic Pain	Pilot human study in knee pain (intraarticular); early-stage data showing tolerability and potential benefit	INVESTIGATIONAL

Musculoskeletal Repair and Recovery

Of all the areas BPC-157 has been studied in, healing of muscles, tendons, and ligaments has received the most attention, and for good reason. Tendons and ligaments are notoriously slow to heal because they get very little blood flow, which is exactly the problem BPC-157’s blood-vessel-growing effect seems to address.³

In animal studies, BPC-157 has been shown to speed the healing of cut Achilles tendons, improve the strength and quality of the repaired tissue, and help tendons reattach to bone, even in animals also given steroids, which normally slow healing.³ Studies in ligaments have shown similar results: better-organized collagen fibers and faster return of function.⁶

In skeletal muscle, BPC-157 has shown effectiveness in animal models of crush injuries, complete tears, and stress-related muscle damage. Importantly, it appears to support not just rebuilding the tissue but also restoring function, the difference between a muscle that looks healed and one that actually works again.³

The 2025 systematic review from HSS Journal reinforced these findings, concluding that BPC-157 consistently improves outcomes in muscle, tendon, ligament, and bone healing across preclinical models, while calling for well-designed human trials to confirm what the animal data strongly suggests.⁵

•   Tendon and Ligament Healing: Animal studies have shown accelerated healing of transected Achilles tendons, improved tissue quality, and superior tendon-to-bone reattachment, even in the presence of corticosteroids that normally impair healing.^3,6

•   Skeletal Muscle Recovery: Preclinical models of crush injury, transection, and metabolic insult have documented both structural repair and functional recovery, a distinction that matters in athletic contexts.³

•   Consistent Cross-Tissue Findings: A 2025 systematic review in HSS Journal concluded that BPC-157 consistently improves outcomes across muscle, tendon, ligament, and bone healing in preclinical models, while calling for well-designed human trials.⁵

Gastrointestinal Protection and Gut Health

Because BPC-157 was originally derived from a protein found in human stomach fluid, it makes sense that its effects on the digestive tract are among the most thoroughly studied. The peptide acts as what scientists call a cytoprotectant (meaning it helps protect cells from damage) throughout the entire digestive system, from the stomach to the colon.⁷

Preclinical research has documented BPC-157’s ability to heal gastric and duodenal ulcers, protect the gut lining from damage caused by NSAIDs and alcohol, and accelerate the healing of intestinal anastomoses (surgical reconnections of the bowel) and colocutaneous fistulas (abnormal channels that form between the colon and the skin).^7,8

Notably, BPC-157 has been evaluated in clinical trials under the designation PL14736 for the treatment of inflammatory bowel disease (IBD), including ulcerative colitis. These trials established its safety profile in human subjects and provided early evidence of its therapeutic potential in GI inflammatory conditions.⁷

Researchers have also explored BPC-157’s role in the brain-gut axis, the bidirectional communication network between the central nervous system and the enteric nervous system (the network of nerves that controls digestion, sometimes called the “second brain”). Studies suggest that BPC-157 may modulate this axis, potentially offering benefits that extend beyond the gut itself to influence mood, stress response, and neurological function.⁹

Neurological Support and the Brain-Gut Connection

BPC-157’s effects on the brain are one of the more interesting areas of research. Studies show that BPC-157 interacts with two of the brain’s main chemical messenger systems: dopamine (which influences motivation and reward) and serotonin (which influences mood). These are the same systems targeted by many common antidepressants and ADHD medications.¹

In animal studies, BPC-157 has acted somewhat like an antidepressant, offset the effects of drugs that disrupt dopamine, and eased withdrawal symptoms in animals dependent on anti-anxiety medications similar to Valium and Xanax. It has also been shown to increase serotonin production in specific brain regions.¹

A 2022 review in Neural Regeneration Research looked specifically at how BPC-157 affects the brain, pointing to its ability to encourage new blood vessel growth and protect brain cells from damage.¹⁰

These findings are encouraging, but the brain-related research on BPC-157 is still at the early animal-study stage. A lot more work is needed before any of this can be applied to people.

Safety Profile and What to Know

One of the things researchers most often note about BPC-157 is its favorable safety record in animal studies. In toxicity testing in rats and beagle dogs, scientists have not been able to identify a dose that causes harm, and they have not seen significant problems with body weight, eating, organ function, or behavior across a wide range of study designs.¹

In the limited human studies conducted to date, including a pilot study on intraarticular knee pain, a study on interstitial cystitis, and a pharmacokinetics safety study, no adverse effects were reported.² BPC-157 was also evaluated in clinical trials for inflammatory bowel disease (as PL14736), where it was confirmed to be safe in human subjects.⁷

A 2025 narrative review from the University of Utah, published in Current Reviews in Musculoskeletal Medicine, summarized the current state of evidence: “BPC-157 demonstrates robust regenerative and cytoprotective effects in preclinical studies, positioning it as a potentially valuable tool in musculoskeletal medicine. Despite its growing popularity among athletes and its wide availability through non-regulated sources, there is minimal human data available. Until well-designed clinical trials are conducted, BPC-157 should be considered investigational, and its use approached with caution.”²

Important Considerations

Most evidence comes from animal studies The majority of BPC-157 research has been conducted in rodent models. While results are promising, animal findings do not always translate to humans.11 No approved human clinical trials completed As of current literature, BPC-157 has not completed large-scale, peer-reviewed human clinical trials for any indication.12 Not FDA approved BPC-157 has no approved therapeutic use. It is an investigational compound and is not legally marketed as a drug or dietary supplement in the United States.13 Compounding pharmacy concerns BPC-157 is sometimes available through compounding pharmacies. Purity, potency, and sterility cannot be guaranteed without independent third-party testing. Long-term safety is unknown There is no established long-term safety data for BPC-157 in humans. The effects of extended use are not known.11 Medical supervision is essential Any use of investigational peptides should only occur under the guidance of a licensed physician.

The Bottom Line: BPC-157 is one of the most extensively studied peptides in preclinical research, with a remarkably broad range of biological effects spanning tissue repair, gut protection, neurological support, and anti-inflammatory activity. The consistency of positive findings across animal models is genuinely compelling, and the compound’s favorable safety profile in the limited human studies conducted so far adds to its appeal.At the same time, the honest answer is that we do not yet have the large-scale human clinical trial data needed to make definitive claims about efficacy in people. The science is promising. The human evidence is still catching up.

Scientific References

1. Jozwiak M, Bauer M, Kamysz W, Kleczkowska P. Multifunctionality and possible medical application of the BPC 157 peptide: literature and patent review. Pharmaceuticals. 2025;18(2):185. https://doi.org/10.3390/ph18020185

2. McGuire FP, Martinez R, Lenz A, Skinner L, Cushman DM. Regeneration or risk? A narrative review of BPC 157 for musculoskeletal healing. Curr Rev Musculoskelet Med. 2025;18(12):611-619. https://doi.org/10.1007/s12178-025-09990-7

3. Gwyer D, Wragg NM, Wilson SL. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell Tissue Res. 2019;377(2):153-159. https://doi.org/10.1007/s00441-019-03016-8

4. Chang CH, Tsai WC, Hsu YH, Pang JHS. Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules. 2014;19(11):19066-19077. https://doi.org/10.3390/molecules191119066

5. Vasireddi N, Hahamyan H, Salata MJ, et al. Emerging use of BPC 157 in orthopaedic sports medicine: a systematic review. HSS J. 2025. https://doi.org/10.1177/15563316251355551

6. Cerovecki T, Bojanic I, Brcic L, et al. Pentadecapeptide BPC 157 (PL 14736) improves ligament healing in the rat. J Orthop Res. 2010;28(9):1155-1161. https://doi.org/10.1002/jor.21107

7. Sikiric P, Seiwerth S, Rucman R, et al. Focus on ulcerative colitis: stable gastric pentadecapeptide BPC 157. Curr Med Chem. 2012;19(1):126-132. https://doi.org/10.2174/092986712803414015

8. Klicek R, Sever M, Radic B, et al. Pentadecapeptide BPC 157, in clinical trials as a therapy for inflammatory bowel disease (PL14736), is effective in the healing of colocutaneous fistulas in rats. J Pharmacol Sci. 2008;108(1):7-17. https://doi.org/10.1254/jphs.FP0072161

9. Sikiric P, Hahm KB, Blagaic AB, et al. Stable gastric pentadecapeptide BPC 157, Robert’s stomach cytoprotection/adaptive cytoprotection/organoprotection, and Selye’s stress coping response. Gut Liver. 2020;14(2):153-167. https://doi.org/10.5009/gnl18490

10. Vukojevic J, Milavic M, Perovic D, et al. Pentadecapeptide BPC 157 and the central nervous system. Neural Regen Res. 2022;17(3):482-487. https://doi.org/10.4103/1673-5374.320969

11. Sikiric P, Seiwerth S, Rucman R, et al. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Current Pharmaceutical Design. 2011;17(16):1612-1632.

12. Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JH. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. Journal of Applied Physiology. 2011;110(3):774-780.

13. Gwyer D, Wragg NM, Wilson SL. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell and Tissue Research. 2019;377(2):153-159.

© 2026 PeptideMatch.io. All Rights Reserved. This educational content is the exclusive intellectual property of PeptideMatch.io. Reproduction, distribution, republication, or transmission of this material, in whole or in part, in any form or by any means, is strictly prohibited without the prior written consent of PeptideMatch.io. For licensing or reprint inquiries, please contact content@peptidematch.io.